Skip to content
Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma

Get the podcast

Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH

The Audio Journal of Oncology

Owen O’Connor

Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New YorkOwen O’Connoralso gave data from early, two studies: one looking at treating lymphoma with the drug SAHA which targets BCL-6 in the tumor preventing it’s anti-apoptotic influence; the other targeting the mTOR signaling pathway with a drug called temsirolimus.

Click here for all the interviews from ASH 2005

Tags

ashdruglymphoma

More from ASH 2005

All 5 interviews

This is the last of the 5 ASH 2005 interviews. See them all.

Related Episodes

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

New Front Line Standard for Older Patients with Chronic Lymphocytic Leukemia

Audio Journal of Oncology SAN DIEGO—The first-line treatment of choice for older patients with chronic lymphocytic leukemia (CLL) should now be single agent ibrutinib according to conclu

24 Jan 2020
3 min
Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

Ibrutinib: New Frontline Standard for Chronic Lymphocytic Leukemia?

SAN DIEGO—Patients 70 years old and younger with previously untreated chronic lymphocytic leukemia (CLL) lived longer and had progression of their disease delayed when treated with ibrutinib (an irrev

7 Oct 2019
10 min
Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia

Chimeric antigen receptor T-cell therapy: high remission rate in relapsed, refractory acute lymphoblastic leukemia

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

19 Dec 2013